本周医药生物行业整体表现稳健，尽管板块略有下跌0.92%，但第十一批国家药品集采顺利开标，中选产品满足了临床和患者的多元需求。此外，“十五五”规划强调支持创新药与医疗器械的发展，为行业长期增长提供了政策支持。恒瑞医药的肾病新药拟纳入优先审评，康龙化成完成了一项重要收购，并发布了第三季度报告。荃信生物-B在强直性脊柱炎Ⅲ期临床研究方面取得进展，并与罗氏达成全球独家许可协议。乐普生物-B的美佑恒在中国...
Source Link本周医药生物行业整体表现稳健，尽管板块略有下跌0.92%，但第十一批国家药品集采顺利开标，中选产品满足了临床和患者的多元需求。此外，“十五五”规划强调支持创新药与医疗器械的发展，为行业长期增长提供了政策支持。恒瑞医药的肾病新药拟纳入优先审评，康龙化成完成了一项重要收购，并发布了第三季度报告。荃信生物-B在强直性脊柱炎Ⅲ期临床研究方面取得进展，并与罗氏达成全球独家许可协议。乐普生物-B的美佑恒在中国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.